Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance

Area of Science:

• Pharmacology and Drug Delivery Systems
• Allergy and Immunology
• Clinical Trial Methodology

Background:

• Consistent medication delivery is crucial for managing allergic rhinitis (AR).
• Current aqueous intranasal corticosteroid devices lack accurate dose counters, potentially leading to poor patient adherence.
• Beclomethasone dipropionate (BDP) nasal aerosol, a non-aqueous formulation, offers a novel device with an integrated dose counter.

Purpose of the Study:

• To evaluate the performance, reliability, and accuracy of the integrated dose counter in a beclomethasone dipropionate (BDP) nasal aerosol device.
• To assess patient adherence and medication delivery consistency in perennial allergic rhinitis (PAR) patients using the BDP nasal aerosol.

Main Methods:

• A 6-week, double-blind, placebo-controlled study involving PAR patients (≥12 years).
• Patients received once-daily BDP nasal aerosol (320 micrograms) or placebo.
• Dose counter accuracy was assessed by comparing patient-reported actuations with device readings, analyzing discrepancies.

Main Results:

• A low overall discrepancy rate of 0.38 per 100 actuations was observed between patient reports and the dose counter.
• The rate of medically significant discrepancies ('fire not count') was very low at 0.09 per 100 actuations.
• The majority of patients (79.1%) reported zero discrepancies, indicating high reliability of the integrated dose counter.

Conclusions:

• The beclomethasone dipropionate (BDP) nasal aerosol device with an integrated dose counter demonstrated functionality and reliability in a clinical setting.
• The accurate dose counter supports consistent medication delivery and may improve patient adherence in managing allergic rhinitis.
• This novel device addresses a critical unmet need for reliable dose tracking in intranasal corticosteroid therapy.